A Phase 1 interventional study of Dabigatran Etexilate in Renal Insufficiency, Chronic, sponsored by Boehringer Ingelheim. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-01-13.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim — none open to participants now, 4 under way, 2 of them phase 3. Renal Insufficiency, Chronic · Boehringer Ingelheim.
Among the 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2012, is one of 2 in phase 1, and was the 1st registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →None of the 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim is open now. The open studies under Renal Insufficiency, Chronic, anywhere →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 242 across the 10 interventional studies, 1,024 across the 3 observational. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
4 of the studies in Renal Insufficiency, Chronic by Boehringer Ingelheim that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06531824Phase 3Boehringer IngelheimEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | 2026-12-31 |
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT07063316Boehringer IngelheimSGLT2 Inhibitors and Renal Anemia in Japan: RWD | 2026-12-25 |
| NCT06527846Boehringer IngelheimPost Marketing Surveillance of JARDIANCE in Chronic Kidney Disease | 2027-03-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study to be conducted is a prospective, open label trial. It is designed to evaluate the pharmacokinetic/pharmacodynamic and coagulation parameters and safety of dabigatran etexilate in patients with chronic kidney disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patient to receive a capsule containing 75 mg of dabigatran etexilate
Drug: Dabigatran Etexilate
Dabigatran Etexilate 75mg twice daily
Cmax,ss
Maximum concentration of Dabigatran etexilate in plasma at steady state was measured. The samples for pharmacokinetics had to be taken from 30 min before drug administration up to 11 days after drug administration.
Time frame: -0.5 hours (h), 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 23.5h, 47.5h, 71.5h, 95.5h, 119.5h, 155.5h, 167.5h, 168.5h, 169h, 170h, 171h, 172h, 174h, 176h, 179.5h, 180h, 192h, 216h, 240h
AUCtau,ss
Area under the plasma concentration-time curve of the total dabigatran at steady state over a uniform dosing interval tau was measured. The samples for pharmacokinetics had to be taken from 30 min before drug administration up to 11 days after drug administration.
Time frame: -0.5 hours (h), 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 23.5h, 47.5h, 71.5h, 95.5h, 119.5h, 155.5h, 167.5h, 168.5h, 169h, 170h, 171h, 172h, 174h, 176h, 179.5h, 180h, 192h, 216h, 240h
| Milestone | Dabigatran 75 mg |
|---|---|
| Started | 19 |
| Completed | 16 |
| Not completed | 3 |
| Withdrew: Not treated | 3 |
Maximum concentration of Dabigatran etexilate in plasma at steady state was measured. The samples for pharmacokinetics had to be taken from 30 min before drug administration up to 11 days after drug administration.
| ng/mL | Dabigatran 75 mg |
|---|---|
| Cmax,ss | 207 ± 53.9 |
Area under the plasma concentration-time curve of the total dabigatran at steady state over a uniform dosing interval tau was measured. The samples for pharmacokinetics had to be taken from 30 min before drug administration up to 11 days after drug administration.
| ng*h/mL | Dabigatran 75 mg |
|---|---|
| AUCtau,ss | 2140 ± 51.9 |
Collected over Up to Day 11. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dabigatran 75 mg | — | 0/16 (0%) | 6/16 (37.5%) |
| Event | Dabigatran 75 mg |
|---|---|
| DiarrhoeaGastrointestinal disorders | 2/16 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/16 |
| NauseaGastrointestinal disorders | 1/16 |
| VomitingGastrointestinal disorders | 1/16 |
| Nail injuryInjury, poisoning and procedural complications | 1/16 |
| WoundInjury, poisoning and procedural complications | 1/16 |
| ThrombophlebitisVascular disorders | 1/16 |
Treated set (TS) which included all patients who had taken at least 1 dose of trial medication.
| Age, Continuous(years) | Dabigatran 75 mg |
|---|---|
| Mean | 72.7 ± 7.6 |
| Sex: Female, Male(Participants) | Dabigatran 75 mg |
|---|---|
| Female | 3 |
| Male | 13 |
The record gives a start of Oct 2012, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dabigatran
Renal Insufficiency, Chronic →